Proposed "Value Framework" Could Limit Patient Access to Myeloma Drugs

The American Society of Clinical Oncology (ASCO) has created a "Value Framework" in an attempt to balance cancer drug costs with value to the patient. In his blog this week, IMF Chariman Dr. Brian Durie examines the framework's point system. "I believe the proposed system does not work well for myeloma," he writes, "and if implemented could limit needed drug access for myeloma patients." To read Dr. Durie's blog, click HERE.
Source: International Myeloma Foundation - Category: Hematology Source Type: news